Bio-Rad Licenses Axis-Shield's Rheumatoid Arthritis Assay | GenomeWeb
NEW YORK (GenomeWeb News) — Bio-Rad Laboratories today said it has licensed Axis-Shield’s early-detection rheumatoid arthritis test.
 
Bio-Rad said the Axis-Shield assay, which is based on anti-CCP antibodies, will run on its BioPlex 2200 system.
 
The BP2200 is an automated multiplexing system that works at a rate of 2,200 results per hour. The platform already holds several assays designed for other autoimmune diseases.
 
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.